Nasal Drug Development, Trends and Challenges with Nasal Formulations
Nanopharm explores the current trends and technical challenges in nasal drug product development, focusing on formulation.
Nanopharm: cGMP Drug Development in OINDP
Nanopharm expands with cGMP facilities for advanced drug development in OINDP. Specializing in biologics characterization and particle engineering.
Nanopharm’s Nasal Spray for SARS-CoV-2 Antibody Treatment
Discover Nanopharm’s innovative nasal spray for SARS-CoV-2. Learn how this prophylactic treatment effectively delivers antibodies for maximum protection.
Nanopharm & Leyden – OINDP Intranasal Sprays vs. Respiratory Viruses
Nanopharm & Leyden Labs collaborate on intranasal sprays for broad protection against respiratory viruses. Focused on OINDP drug development.
Raman Spectroscopy for Nasal Suspension Drugs
Explore a systematic approach in developing Morphologically-Directed Raman Spectroscopy for characterizing nasal suspension drug products.
Assessing Particle Size in DPIs with Spraytec & Unidose
Assess setups to combine Spraytec & Unidose™ for evaluating particle size distribution in dry powder inhalers.
Simulation in In Vitro Bioequivalence for Particle Sizes
Explore Simulation-informed design in in-vitro bioequivalence trials for particle size distributions’ performance.
In Vitro System for Orally Inhaled Drug Release
Discover the development of an in vitro dissolution and release system from Nanopharm for OINDPs (orally inhaled drug products).
Raman Spectroscopy for Nasal Suspension Drugs
Explore a systematic approach in developing Morphologically-Directed Raman Spectroscopy for characterizing nasal suspension drug products.
Faster, Cost-Effective Alternative to Generic Bioequivalence
Discover SmartTrack to advance the development of OINDPs. Streamline inhalation and nasal therapies with optimized particle size distribution.
